TG Therapeutics reported third-quarter 2025 revenue of $161.7 million, including $152.9 million in U.S. Briumvi net sales. It raised full‑year guidance to approximately $585 million for Briumvi U.S. revenue and $600 million in total global revenue. The company advanced two label- and lifecycle-enabling Phase 3 programs—subcutaneous ublituximab and a simplified intravenous initiation regimen consolidating day 1 and day 15 dosing into a single 600 mg infusion—while expanding ex‑U.S. commercialization with Neuraxpharm across the EU, UK, Switzerland, Australia, Kuwait, and the UAE. A completed $100 million share repurchase and authorization of another $100 million underscore confidence in the cash-generation profile tied to Briumvi.
The strategic question is whether TG can convert a fast-growing anti‑CD20 asset into a defensible MS franchise before the next convenience wave and biosimilar pressure reshape the category. The plan is clear: use convenience, operational efficiency, and real-world evidence to press share gains against established anti‑CD20 competitors and to blunt the appeal of self‑administered options. If the single‑infusion initiation and the subcutaneous program succeed, Briumvi could anchor a dual‑mode platform that gives prescribers flexibility and payers a cleaner total-cost story.
This matters now because the MS market’s center of gravity has shifted decisively toward B‑cell depletion, while BTK inhibitors continue to face safety and regulatory uncertainty. For neurologists and infusion centers, a consolidated first dose, combined with Briumvi’s short maintenance infusion time, can reduce chair time, staffing complexity, and scheduling friction—tangible enablers of adoption in capacity-constrained sites of care. For patients, fewer visits at initiation and faster infusion rates can improve the experience and adherence. For payers, simplifying administration can yield line‑item savings on infusion services and may reduce discontinuation-related waste, strengthening the pharmacoeconomic narrative in a class where drug-acquisition costs are similar.
The evidence engine is also pointed at access and retention. Six‑year open‑label extension data from the ULTIMATE program reported nearly 90% of relapsing MS patients free from 24‑week confirmed disability progression with no new safety signals. This message reinforces the durability of clinical decision-making. Early real‑world readouts from the ENABLE observational study align with pivotal outcomes, providing Medical Affairs teams with additional material for payer dossiers and HCP education. While open‑label and RWE datasets carry inherent limitations, they are increasingly influencing formulary maintenance and prior authorization policies for chronic neurologic conditions.
Financially, TG is behaving like a focused, cash‑generative specialty player. R&D spend rose to $40.9 million in the quarter as the subcutaneous program ramps, SG&A reached $63.4 million as the field and marketing footprint expands, and net income of $390.9 million included a non‑recurring $365 million tax benefit from releasing a valuation allowance. Cash and investments were $178.3 million at quarter‑end, with operating contributions from Briumvi expected to fund ongoing development. The additional buyback authorization signals balance-sheet confidence, but it also tightens the timeline to demonstrate pipeline breadth beyond MS or to transact BD that diversifies revenue.
The following 12 months will test whether convenience-led lifecycle management can entrench Briumvi as a prescriber default amid competitive countermoves in subcutaneous delivery and the approach of anti‑CD20 biosimilars. Suppose the label‑enabling dosing study and the subcutaneous Phase 3 deliver. Can TG translate clinical and operational wins into durable formulary preference and global scale before the market’s next innovation cycle resets the bar?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
